Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Additional Listing

22 Mar 2011 10:11

RNS Number : 3828D
Avacta Group PLC
22 March 2011
 



 

 

22 March 2011

 

 

Avacta Group plc

 

Issues of Equity

 

Avacta Group plc (the "Company") announces that 28,500,000 ordinary shares of 0.1p each ("Ordinary Shares") have been issued at a price of 0.25p per share, pursuant to the exercise of share warrants. The warrants were granted during May 2006, prior to the reversal of Avacta Limited into the Company, then named Readybuy plc.

Application has been made for the 28,500,000 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 23 March 2011.

The Company also announces that a further 500,000 Ordinary Shares have been issued at a price of 0.25p per share, pursuant to the exercise of share warrants similarly granted during May 2006. Application has also been made for these 500,000 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 25 March 2011.

The total number of Ordinary Shares, with voting rights, in issue following the above two issues of shares will be 1,664,487,577.

 

 

Enquiries:

 

Avacta Group plc

Tel: 0844 414 0452

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

www.avacta.com

Broker

XCAP Securities Limited

John Grant/Karen Kelly/David Newton

Nominated Adviser

Grant Thornton Corporate Finance

Tel: 020 7101 7070

www.xcapgroup.com

 

Tel: 020 7383 5100

www.grantthornton.co.uk

Colin Aaronson/David Hignell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISLLFIIVRIFFIL
Date   Source Headline
21st Aug 201712:00 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSTrading Update
31st Jul 201712:00 pmRNSIssue of Equity
28th Jul 20171:15 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSDirector Dealing and Issue of Equity
4th Jul 20177:00 amRNSManchester ShareSoc Growth Company Seminar
5th Jun 20177:00 amRNSShareSoc Growth Company Seminar
1st Jun 20178:56 amRNSIssue of Equity
22nd May 20177:00 amRNS2 Biotech's Licence Affimers for Research Use
10th May 20177:00 amRNSKey Affimer Patent To Be Granted in China
8th May 20171:21 pmRNSHardman Research: De-risking Moderna's partnership
5th May 20177:00 amRNSPresenting at the Hardman Private Investor Forum
2nd May 20177:00 amRNSAvacta to Present at BioTrinity 2017
24th Apr 20177:00 amRNSDiagnostics firm take rights to several Affimers
19th Apr 20177:00 amRNSAvacta to Present at the Shares Spotlight Evening
12th Apr 20177:15 amRNSHardman Research: Another important box ticked
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 201710:22 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSInterim Results for the Period Ended 31 Jan 2017
3rd Apr 20177:00 amRNSResults of Immunogenicity Study with Human Samples
31st Mar 20179:31 amRNSAvacta Presents at Investor Evening Hosted by TPI
31st Mar 20177:00 amRNSLondon Growth and Innovation Forum Presentation
22nd Mar 20179:00 amRNSAvacta to present at the UK Investor Show
21st Mar 20177:15 amRNSHardman Research: Low response would be positive!
30th Jan 20177:00 amRNSDirector/PDMR Shareholding
20th Jan 201711:35 amRNSResult of Annual General Meeting
20th Jan 20177:00 amRNSTrading Update
11th Jan 20177:00 amRNSPresenting at London Growth and Innovation Forum
5th Jan 20177:00 amRNSDirector Dealing and Issue of Equity
20th Dec 20167:00 amRNSDirector/PDMR Shareholding
16th Dec 20165:14 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSNotice of AGM, Accounts and Directorate Change
23rd Nov 20167:00 amRNSTechnical Update: Affinity Separation
7th Nov 20167:00 amRNSCancer Expert joins Scientific Advisory Board
2nd Nov 20167:00 amRNSCAR-T Cell Therapy Research Collaboration in US
1st Nov 20167:00 amRNSResults from first Affimer pre-clinical studies
21st Oct 201611:39 amRNSDirector's Dealing
17th Oct 20161:00 pmRNSHardman Research: Great strides to strategic goals
17th Oct 20167:00 amRNSPrelim Results for the Year Ended 31 July 2016
4th Oct 20163:28 pmRNSIssue of Equity
26th Sep 201611:21 amRNSNotice of Results
22nd Sep 20167:00 amRNSPositive results from first preclinical studies
12th Sep 20167:00 amRNSChange of Adviser
31st Aug 20162:17 pmRNSChange of Registered Office
16th Aug 20167:00 amRNSNew Facilities in Cambridge and Wetherby
10th Aug 20167:00 amRNSGrant Funding
3rd Aug 20167:00 amRNSKey Affimer patents to be granted in Europe and US
1st Aug 20167:00 amRNSTrading Statement
19th Jul 20163:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.